CA2046943A1 - Procede de production d'un agent ayant comme substance active de la flupirtine et visant a soulager la tension musculaire - Google Patents

Procede de production d'un agent ayant comme substance active de la flupirtine et visant a soulager la tension musculaire

Info

Publication number
CA2046943A1
CA2046943A1 CA2046943A CA2046943A CA2046943A1 CA 2046943 A1 CA2046943 A1 CA 2046943A1 CA 2046943 A CA2046943 A CA 2046943A CA 2046943 A CA2046943 A CA 2046943A CA 2046943 A1 CA2046943 A1 CA 2046943A1
Authority
CA
Canada
Prior art keywords
agent
producing
active substance
muscular tension
combat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2046943A
Other languages
English (en)
Other versions
CA2046943C (fr
Inventor
Michael Lobisch
Ralph Venhaus
Bernd Nickel
Istvan Szelenyi
Jurgen Engel
Peter Emig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2046943A1 publication Critical patent/CA2046943A1/fr
Application granted granted Critical
Publication of CA2046943C publication Critical patent/CA2046943C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Paints Or Removers (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002046943A 1990-07-14 1991-07-12 Procede de production d'un agent ayant comme substance active de la flupirtine et visant a soulager la tension musculaire Expired - Lifetime CA2046943C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP4022442.2 1990-07-14
DE4022442 1990-07-14
IN421CA1991 IN172468B (fr) 1990-07-14 1991-06-04

Publications (2)

Publication Number Publication Date
CA2046943A1 true CA2046943A1 (fr) 1992-01-15
CA2046943C CA2046943C (fr) 1996-03-12

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002046943A Expired - Lifetime CA2046943C (fr) 1990-07-14 1991-07-12 Procede de production d'un agent ayant comme substance active de la flupirtine et visant a soulager la tension musculaire

Country Status (30)

Country Link
US (2) US5162346A (fr)
EP (2) EP0467164B1 (fr)
KR (1) KR0182811B1 (fr)
CN (1) CN1070700C (fr)
AT (2) ATE206919T1 (fr)
AU (1) AU634073B2 (fr)
CA (1) CA2046943C (fr)
CZ (1) CZ280879B6 (fr)
DE (3) DE59109222D1 (fr)
DK (2) DK0659410T3 (fr)
EG (1) EG19814A (fr)
ES (2) ES2082887T3 (fr)
GR (1) GR3019179T3 (fr)
HR (1) HRP920667B1 (fr)
HU (1) HU206973B (fr)
IE (1) IE74688B1 (fr)
IL (1) IL98810A (fr)
IN (1) IN172468B (fr)
LT (1) LT3593B (fr)
LV (1) LV10048B (fr)
MC (1) MC2272A1 (fr)
MX (1) MX9100160A (fr)
NO (1) NO912758L (fr)
NZ (1) NZ238940A (fr)
PT (1) PT98291B (fr)
RO (1) RO108220B1 (fr)
RU (1) RU2070408C1 (fr)
SI (1) SI9111227B (fr)
SK (1) SK279567B6 (fr)
ZA (1) ZA915466B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
CZ2002411A3 (cs) * 1999-08-03 2003-03-12 Awd. Pharma Gmbh & Co. Kg Farmaceutický prostředek pro léčení bolesti stejně jako prevenci chronických bolestí při degenerativních chorobách kloubů u psů a koček
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
WO2005072705A1 (fr) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combinaison d'antagoniste de recepteur nmda et d'inhibiteur mao ou gadpf pour le traitement d'affections liees au systeme nerveux central
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (fr) * 2005-01-31 2006-08-09 elbion AG Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
US20090318507A2 (en) * 2006-05-02 2009-12-24 Chris Rundfeldt Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
PT2061465E (pt) * 2006-08-23 2013-07-15 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil)anilidas como moduladores do canal de potássio
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8030518B2 (en) * 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EA201070189A1 (ru) * 2007-08-01 2010-08-30 Х. Лундбекк А/С Применение соединений, открывающих калиевые каналы kcnq, для подавления симптомов или лечения расстройств или состояний, при которых нарушается дофаминергическая система
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
ATE46265T1 (de) * 1985-01-23 1989-09-15 Asta Pharma Ag Synergistische kombination von flupirtin und nicht-steroidalen antiphlogistika.
EP0193056B1 (fr) * 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Combinaison de la flupirtine avec des spasmolytiques à effet anticholinergique
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A (fi) * 1985-06-28 1986-12-29 Degussa Synergistisk kombination av flupirtin och 4-acetamido-fenol.

Also Published As

Publication number Publication date
HUT59313A (en) 1992-05-28
NO912758D0 (no) 1991-07-12
DK0467164T3 (da) 1996-03-04
MX9100160A (es) 1992-02-28
PT98291A (pt) 1992-05-29
EP0467164A3 (en) 1992-04-15
ES2082887T3 (es) 1996-04-01
HRP920667B1 (en) 1998-06-30
PT98291B (pt) 1999-01-29
ATE133564T1 (de) 1996-02-15
IE74688B1 (en) 1997-07-30
LTIP919A (en) 1995-03-27
US5284861A (en) 1994-02-08
DK0659410T3 (da) 2001-12-27
DE59107331D1 (de) 1996-03-14
EP0467164A2 (fr) 1992-01-22
LV10048A (lv) 1994-05-10
EP0659410B1 (fr) 2001-10-17
CZ280879B6 (cs) 1996-04-17
AU634073B2 (en) 1993-02-11
SI9111227A (en) 1995-06-30
ZA915466B (en) 1992-04-29
MC2272A1 (fr) 1993-06-23
SK279567B6 (sk) 1999-01-11
RU2070408C1 (ru) 1996-12-20
EP0659410A3 (fr) 1995-10-25
KR920002147A (ko) 1992-02-28
IL98810A0 (en) 1992-07-15
LT3593B (en) 1995-12-27
LV10048B (en) 1995-06-20
HU206973B (en) 1993-03-01
CA2046943C (fr) 1996-03-12
IN172468B (fr) 1993-08-14
ES2164111T3 (es) 2002-02-16
CS210191A3 (en) 1992-02-19
KR0182811B1 (ko) 1999-05-01
RO108220B1 (ro) 1994-03-31
GR3019179T3 (en) 1996-06-30
CN1070700C (zh) 2001-09-12
IL98810A (en) 1996-01-19
EG19814A (en) 1996-02-29
IE912451A1 (en) 1992-01-15
HRP920667A2 (en) 1996-10-31
EP0467164B1 (fr) 1996-01-31
NZ238940A (en) 1997-05-26
US5162346A (en) 1992-11-10
CN1058716A (zh) 1992-02-19
HU912359D0 (en) 1991-12-30
SI9111227B (sl) 2000-12-31
ATE206919T1 (de) 2001-11-15
NO912758L (no) 1992-01-15
DE59109222D1 (de) 2001-11-22
AU8040391A (en) 1992-01-16
EP0659410A2 (fr) 1995-06-28
DE4122166A1 (de) 1992-01-16

Similar Documents

Publication Publication Date Title
CA2046943A1 (fr) Procede de production d'un agent ayant comme substance active de la flupirtine et visant a soulager la tension musculaire
HUT50794A (en) Herbicides comprising substituted benztriazole derivatives as active ingredient and process for producing the active ingredients
CA2009735A1 (fr) Composes nitro actifs comme insecticides
NO880182L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,2-dihydro-3h-indazol-3-on-derivater.
HUT48605A (en) Fungicides comprising hydroxyalkylazolyl derivatives as active ingredient and process for producing the active ingredient
IE791235L (en) Acyl-derivatives of carnitine.
HUT44908A (en) Fungicides comprising triazolyl- or imidazolyl-group-substituted 2,5-dihydrofuran derivatives as active ingredient and process for producing the active ingredient and intermediaries thereof
HUT49875A (en) Herbicides comprising substituted sulfonylaminoazole derivatives as active ingredient and process for producing the active ingredients
NO885598D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive ammoniumforbindelser.
HUT47794A (en) Insecticide, acaricide and nematocide compositions containing pyridazinone derivatives as active components and process for producing the active components
HUT48623A (en) Herbicides comprising 2,5-dihydropyrrole derivatives as active ingredient and process for producing 2,5-dihydropyrrole derivatives
NO900697D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive acetamid-derivater.
CA2135709A1 (fr) Derives de melatonine servant au traitement des troubles du sommeil
HUT45049A (en) Herbicides comprising triazole-pyrimidine-2-sulfonamides as active ingredient and process for producing the active ingredient
HUT49596A (en) Herbicides comprising iminophenylthiazolidine derivatives as actie ingredient and process for producing the active ingredients
IE821172L (en) Anticonvulsant benzamides
HUT46659A (en) Process for producing pyrrolidine-2-(1,3-dicarbonyl) derivatives and pharmaceuticals comprising the same as active ingredient
NO881768L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner.
NO168040C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3'-demetoksyepipodofyllotoksin-glukosidderivater.
NO167739C (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive ginkolid-derivater.
HUT49873A (en) Herbicides and acaricides, as well as process for producing the active ingredient aryl- or heteroaryldione derivatives
HUT53891A (en) Nematocide insecticide and acaricide comprising 5-substituted-3-arylisoxazole derivatives as active ingredient and process for producing the active ingredients
ES8203086A1 (es) Un procedimiento para la produccion de n,n'-bis-(3-picolil) -4-metoxi-isoftalamida monohidratada
HUT46881A (en) Herbicides comprising cyclohexane-1,3,5-triones as active ingredient and process for producing the active ingredients
NO860091L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 12-amino-pyridazino(4[,5[:3,4)pyrrolo(2,1-a)isokinolin-derivater.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry